We evaluated the relationship between CMV and human herpes virus-6 (HHV-6) reactivation and the incidence of grades 2 to 4 acute GVHD post BMT. Bronchoalveolar lavage fluid (BALF) samples extracted from 54 BMT recipients on post-BMT day 35 were analyzed by PCR for detection of CMV DNA, HHV-6 DNA and CMV plus HHV-6 DNA. CMV DNA was detected in 26 patients and 13 (50%) developed grades 2 to 4 acute GVHD. Of the 28 who were CMV negative, only six (21.4%) developed grades 2 to 4 acute GVHD. HHV-6 was detected in 18 patients, and 11 (61.1%) developed grades 2 to 4 acute GVHD. Of the 36 who were HHV-6 negative, only eight (22.2%) developed grades 2 to 4 acute GVHD. CMV and HHV-6 were detected in 13 patients, and eight (61.5%) developed grades 2 to 4 acute GVHD. Of the 23 who were negative for both CMV and HHV-6, only three (13%) developed grades 2 to 4 acute GVHD. In all experiments, the difference between the groups was significant (P Ͻ 0.05, P Ͻ 0.05 and P Ͻ 0.01, respectively). We conclude that herpes virus infection, in particular CMV concurrent with HHV-6 reactivation, is predictive of moderate to severe acute GVHD. Bone Marrow Transplantation (2000) 26, 77-81. Keywords: CMV; HHV-6; GVHD; BMT; bronchoalveolar lavage fluids
sion. 2, 3 Acute GVHD is also a major adverse consequence of BMT. 4 It is well documented that moderate to severe GVHD (grades 2 to 4) indicates rapid progression to CMV disease. However, the effect of herpes virus infections on the severity of acute GVHD remains controversial. 5, 6 Early detection of CMV DNA and HHV-6 DNA may be a key factor in survival from CMV-IP and GVHD. 7 One useful technique for these viruses is the PCR surveillance of bronchoalveolar lavage fluids (BALF). We analyzed BALF samples of post-BMT recipients for the reactivation of CMV and HHV-6 and the incidence of GVHD to determine whether there is a relationship between these infections and GVHD.
Patients and methods

Eligibility
Between April 1991 and April 1998, 91 patients underwent allogeneic BMT at our institution. Our study subjects were taken from this patient population.
To be eligible for our study, patients had to be able to undergo bronchoscopy and had to have a performance status of 0 to 2, but did not have to have interstitial pneumonitis or active pneumonia (as revealed on chest X-ray). Patients in whom grade 2 or higher acute GVHD developed before day 35 post BMT were excluded. Thirty-seven of the 91 patients were excluded. They consisted of 17 patients with acute GVHD of more than grade 2, performance status of more than three in 10 patients, difficulty of fiber optic bronchoscope in four patients and early death in one patient. Five patients had bronchoscopy performed, but were not examined for HHV-6 by PCR. Three of those excluded patients had developed CMV-IP on post-BMT days 58, 97 and 156, and all of them died of the disease. No one developed HHV-6-related disease in the excluded patient group. Fifty-four of the 91 BMT patients met the criteria for our study and were enrolled. Informed consent was obtained from all patients.
BMT characteristics
Characteristics based on virus positivity in BALF are detailed in Tables 1 and 2 . In general, BU plus CY with fractionated TBI was the conditioning regimen 8 in patients who underwent unrelated donor transplants, patients with ALL and patients with high risk disease status at the time of BMT. The high-risk group included patients with acute leukemia beyond first relapse, those with CML with accelerated and blastic phase, and those with MDS more advanced than refractory anemia with excess myeloblasts (RAEB). BU and CY without TBI was used for patients who received related donor transplants and patients at standard risk. The standard risk group included patients with Table 2 Transplant characteristics based on CMV and HHV-6 DNA positivity in BALF    TBI regimen is defined BU+CY+TBI or CY+TBI. Non-TBI is defined BU+CY or CY+ATG. s-MTX, short term methotrexate; MP, methylprednisolone; *, statistical analysis by chi-square test showed no significant difference in conditioning regimen, type of donor, and GVHD prophylaxis between the group with positive isolates and the one without in both CMV and HHV-6 group.
acute leukemia in first remission, those with CML in chronic phase, those with MDS as refractory anemia (RA), and those with severe aplastic anemia. Prior to BMT, 52 donors and 52 recipients were shown to be CMV seropositive (enzyme-linked immunosorbent assay, cytomegalo Ig-G-EIA; Denkaseiken, Tokyo, Japan). One pair included a seronegative donor and a seropositive recipient; another pair included a seronegative recipient and a seropositive donor (Table 2) . Whenever CMV was detected in the BALF, pre-emptive treatment with ganciclovir 9,10 was started at a dose of 5 mg/kg i.v. every 12 h for 1 or 2 weeks as described elsewhere. 7 No specific therapy was performed for HHV-6 PCR-positive patients. All patients received platelet transfusions and irradiation with 25 Gy. All patients received prophylactic acyclovir at 5 mg/kg i.v. every 8 h beginning 1 day before transplant until engraftment was complete. All recipients received anti-CMV, high-titer immunoglobulin i.v. at a dose of 12.5g every 2 weeks beginning after BMT for 3 months.
PCR analysis for CMV and HHV-6
DNA was extracted from BALF specimens of recipients post BMT using an IsoQuick nucleic acid extraction kit (MicroProbe, Garden Grove, CA, USA) as previously described. 7 In brief, the PCR primers were 5′-TTGCAGGCCACGAACAACGT-3′ and 5′-GTCTACGG ATTGCTGACGTC-3′. The PCR product for CMV was 305 bp in length, and the PCR product for HHV-6 (variant B) was 423 bp in length. 11 The PCR results were not quantified.
Statistical analyses
The chi-square test was used to analyze CMV positivity, HHV-6 positivity, and CMV and HHV-6 positivity in the BALF of BMT recipients. Statistics are shown in Tables 1,  2 
Results
Fifty-four BMT recipients were evaluated by PCR to detect CMV in BALF specimens obtained on day 35 post-BMT. At this point, no patient had developed acute GVHD higher than grade 2. Patient and transplant characteristics are shown in Tables 1 and 2 . Results of the chi-square test analyses for CMV positivity, HHV-6 positivity, and CMV and HHV-6 positivity are shown in Tables 1, 2 and 3 , and illustrated in Figure 1 .
CMV positivity
Twenty-six of the 54 BMT recipients were shown by PCR analysis to be CMV DNA-positive, and 13 (50%) of them developed grades 2 to 4 acute GVHD. The other 28 patients were CMV DNA-negative and, among them, six (21.4%) developed grades 2 to 4 acute GVHD. The difference CMV and HHV-6
HHV-6 CMV and HHV-6 **P < 0.01 *P < 0.05 *P < 0. Bone Marrow Transplantation between these groups with respect to development of grades 2 to 4 acute GVHD was significant (P Ͻ 0.05, Table 3 , Figure 1 ).
HHV-6 positivity
Eighteen of the 54 BMT recipients were shown by PCR analysis to be HHV-6 DNA-positive compared with 36 who were HHV-6-negative. Eleven (61.1%) of those who were HHV-6-positive developed grades 2 to 4 acute GVHD, whereas only eight (22.2%) of those who were HHV-6-negative developed grades 2 to 4 acute GVHD. The difference between these groups with respect to development of grades 2 to 4 acute GVHD was significant (P Ͻ 0.05, Table 3 , Figure 1 ).
CMV and HHV-6 positivity
Thirteen of 54 BMT recipients were shown by PCR analysis to be positive for both CMV and HHV-6. Of these 13 patients, eight (61.5%) developed grades 2 to 4 acute GVHD. Twenty-three were shown to be negative for both CMV and HHV-6. Of these 23, only three (13%) developed grades 2 to 4 acute GVHD. The difference between these groups with respect to development of grades 2 to 4 acute GVHD was significant (P Ͻ 0.01, Table 3 , Figure 1 ).
Relationship between grade of acute GVHD and CMV/HHV-6 positivity
Outcome of grades of GVHD is shown in Table 4 as of December 1998. Prior to the study, 10 patients had already developed GVHD grade 1, and five patients had complicated GVHD grade 1 beyond day 35 post BMT. Of those eight patients with CMV DNA-positive and low grade GVHD in Table 4 six patients were on steroids for GVHD prophylaxis. Among five patients with HHV-6-positive and low grade GVHD, four patients were on steroids. (n = 13) (n = 6) (n = 11) (n = 8) 4
As of December 1998.
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Variables affecting herpes virus positivity
There were no statistically significant differences in sex, disease status at BMT, conditioning regimen, type of donor, and GVHD prophylaxis in the group with positive DNA results and the negative group by chi-square test (Tables 1, 2) .
Causes of death
Outcome according to the grades of acute GVHD is shown in Table 5 .
Discussion
Research which has focused on antigenemia and/or PCR analysis of peripheral blood leukocytes 12, 13 and BALF [14] [15] [16] has increased our understanding of CMV infections following BMT. The rate of CMV positivity of BALF is superior to that of peripheral blood. (47.2% vs 30.9%, P Ͻ 0.05, unpublished data). This indicates a high sensitivity in the BALF samples. In the present study, we performed PCR analysis on BALF samples collected from post-BMT patients to determine the presence of herpes viruses CMV and HHV-6 and the relationship between the presence of these viruses and the occurrence of grades 2 to 4 acute GVHD.
Our results show that the presence of herpes virus infections CMV and HHV-6 is a strong indicator for grades 2 to 4 acute GVHD in this patient population. For our analysis, the BALF samples were examined on day 35 post BMT. Because of our eligibility criteria, none of our study subjects had grades 2 to 4 acute GVHD prior to bronchoscopy. Patients with early onset acute GVHD were excluded in this study. Thus, our study shows that CMV and HHV-6 might enhance immune system reactivity or alter the antigenicity of the host tissue, thereby leading to an increased incidence of GVHD. There is also the possibility that herpes virus infections in BALF precede the onset of GVHD; that is, such viruses might exacerbate or initiate GVHD. This study is the first to use PCR results of herpes virus DNA in BALF on day 35 post BMT as a predictor for GVHD. In contrast to our results, many investigators 6,13 have reported that GVHD usually precedes CMV infection. In other studies, 17 GVHD has been shown to be the main risk factor for CMV-IP. Appleton et al 13 stated that CMV has been shown not to be a risk factor for development of acute or chronic GVHD based on a prospective study of skin and rectal biopsy sample. In contrast, a retrospective study showed that acute GVHD is not a significant risk factor for CMV infection and disease in the multivariate analysis. 5 A recent report 12 suggests that detection rates of CMV DNA or HHV-6 DNA in peripheral blood are higher in patients with grades 2 to 4 acute GVHD than are detection rates of these viruses in patients with grades 0 to 1 acute GVHD. However, in those studies, the incidence of grades 2 to 4 acute GVHD did not significantly correlate with CMV DNA and HHV-6 DNA. It should be noted that their study used peripheral blood samples rather than BALF. Therefore, their results are not comparable with ours.
In an animal model, CMV was shown to lower the threshold necessary to induce a GVH reaction. 18 In addition, the relationship between HHV-6 and acute GVHD in post-BMT patients was clarified in a study that showed a significant correlation between the results of HHV-6 positivity and severity of acute GVHD. 2 Based on these studies, two different hypotheses can be derived regarding the relationship between herpes virus and GVHD: (1) herpes virus infections may augment GVHD by changing the host immune system; and (2) GVHD may augment reactivation of herpes virus infections, which are associated with a number of immunological changes. To clarify the mechanisms of action of herpes viruses and GVHD, further research should be performed at the molecular level of viral infections and involving the host immune system in an animal model.
In conclusion, this study shows that in BMT patients with CMV-positive BALF on day 35 post BMT, concurrent infection and/or reactivation of HHV-6 is associated with an increased risk of progression to grades 2 to 4 acute GVHD.
